Notícias Clearside Biomedical Inc - CLSD | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Clearside Biomedical Inc (CLSD)
Clearside Biomedical Inc (CLSD) Notícias

Clearside Biomedical Inc (CLSD)

0,8501

0,0501

(6,26%)

Fechado 05 Março 6:00PM

Atrasado por 15 minutos

0,949

0,0989

( 11,63% )

Pré-mercado: 9:44AM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Form 8-K - Current report

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Form 4 - Statement of changes in beneficial ownership of securities

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Form 8-K - Current report

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Clearside Biomedical

Deutsche Effecten Und We...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições